Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

BIOVERSYS LAUNCHES IPO ON THE SIX SWISS EXCHANGE AND SETS IPO PRICE AT CHF 36.00 PER SHARE » Report
Arbonia AG: Antitrust approval of the EU Commission obtained for the sale of the Climate Division » Report
Arbonia AG: Kartellrechtliche Genehmigung der EU-Kommission für Verkauf der Division Climate liegt vor » Report
Change to the Roche Enlarged Corporate Executive Committee » Report
Adecco Groups Partners with Bullhorn to Drive AI Powered Recruitment Innovation as Part of its Global AI Strategy » ADECCO
Interroll Holding AG: Good profitability in a difficult economic environment » Report
Avolta Capital Markets Day 2025 - Save The Date » Report
Rieter – Significant Increase in Order Intake in Financial Year 2024 Ad-hoc announcement pursuant to Art. 53 LR » Report
Rieter – deutliche Steigerung des Bestellungseingangs im Geschäftsjahr 2024 Ad hoc-Mitteilung gemäss Art. 53 KR » Report
Lonza Group AG: Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin » Report
Lonza Group AG: Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29.0% Kern-EBITDA-Marge » Report
Logitech - Logitech Announces Fourth Consecutive Quarter of Sales Growth » Report
GUTEN ABEND: DAILY SMI +0,31% 12'455 SMI Top LONN +1,5% ALC +1,4% ZURN +1% NESN SCMN SLHN +0,8% Flop ABBN -1,7% PGHN -1% SOON -0,4% GIVN -0,3% CFR -0,1% SIKA flat +++ VSMI +2,03% 12.78 (12.52) +++ DAX +0,70% 21’430 +++ Strasse stabil bis fester +++ (ohne Gewähr)
Temenos appoints Sairam Rangachari as Chief Product Officer » Report
SWISS INDICATIONS: A friendly SMI, friendly Logitech, Novartis, Roche, UBS, bullish Comet, Basilea, Tecan, friendly VAT, weak Adecco are the facts. The other stocks are holding up well. Source cashInsider
SCHWEIZER INDIKATIONEN: Ein freundlicher SMI, freundliche Logitech, Novartis, Roche, UBS, haussierende Comet, Basilea, Tecan, freundliche VAT, schwache Adecco die Fakten. Gut gehalten tendieren die übrigen Titel. Quelle cashInsider
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer » Report
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea » Report
Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus » Report